Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines

N. Zaffaroni, L. Orlandi, D. Gornati, C. De Marco, M. Vaglini, R. Silvestrini

Research output: Contribution to journalArticle

Abstract

The potential of the purine analogue fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine-5 monophosphate) as a modulator of cisplatin cytotoxicity was investigated in four established cell lines and 20 primary cultures of human melanoma and ovarian cancer. Tumour cells were exposed to fludarabine and cisplatin, alone or in combination, for 4 h. Fludarabine did not affect the growth of ovarian cancer cell lines, whereas it induced a marked and dose-dependent inhibition of proliferation in melanoma cell lines. In primary cultures of both histotypes, the purine analogue did not induce appreciable antiproliferative effects. Combined cisplatin-fludarabine treatment caused additive effects in all established cell lines. Conversely, a synergistic effect of the combination was seen in 5 of 10 melanoma and 4 of 10 ovarian cancer primary cultures, with a dose-modifying factor ranging from 2.1 to 3.9 for melanomas and from 4.0 to 7.5 for ovarian cancers, respectively. In the remaining cultures, the interaction between fludarabine and cisplatin was additive. The alkaline filter elution analysis performed on primary cultures showed that the synergistic interaction between the two drugs was paralleled by an increase in the extent and persistence of the cisplatin-induced DNA interstrand crosslinks. Our results indicate that fludarabine can enhance cisplatin cytotoxic activity in human tumour primary cultures from ovarian cancer and malignant melanoma. Such an effect may be partially due to an interference by fludarabine on cisplatin-induced DNA adduct metabolism and repair.

Original languageEnglish
Pages (from-to)1758-1765
Number of pages8
JournalEuropean Journal of Cancer
Volume32
Issue number10
Publication statusPublished - 1996

Fingerprint

Human Activities
Cisplatin
Ovarian Neoplasms
Cell Line
Melanoma
Neoplasms
fludarabine
DNA Repair
DNA
Growth
Pharmaceutical Preparations

Keywords

  • Cisplatin
  • Cytotoxicity
  • Dna repair
  • Fludarabine
  • Malanoma
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Zaffaroni, N., Orlandi, L., Gornati, D., De Marco, C., Vaglini, M., & Silvestrini, R. (1996). Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. European Journal of Cancer, 32(10), 1758-1765.

Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. / Zaffaroni, N.; Orlandi, L.; Gornati, D.; De Marco, C.; Vaglini, M.; Silvestrini, R.

In: European Journal of Cancer, Vol. 32, No. 10, 1996, p. 1758-1765.

Research output: Contribution to journalArticle

Zaffaroni, N, Orlandi, L, Gornati, D, De Marco, C, Vaglini, M & Silvestrini, R 1996, 'Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines', European Journal of Cancer, vol. 32, no. 10, pp. 1758-1765.
Zaffaroni, N. ; Orlandi, L. ; Gornati, D. ; De Marco, C. ; Vaglini, M. ; Silvestrini, R. / Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines. In: European Journal of Cancer. 1996 ; Vol. 32, No. 10. pp. 1758-1765.
@article{23cb195f9ec04fbbbc9b3458d5fe4d5a,
title = "Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines",
abstract = "The potential of the purine analogue fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine-5 monophosphate) as a modulator of cisplatin cytotoxicity was investigated in four established cell lines and 20 primary cultures of human melanoma and ovarian cancer. Tumour cells were exposed to fludarabine and cisplatin, alone or in combination, for 4 h. Fludarabine did not affect the growth of ovarian cancer cell lines, whereas it induced a marked and dose-dependent inhibition of proliferation in melanoma cell lines. In primary cultures of both histotypes, the purine analogue did not induce appreciable antiproliferative effects. Combined cisplatin-fludarabine treatment caused additive effects in all established cell lines. Conversely, a synergistic effect of the combination was seen in 5 of 10 melanoma and 4 of 10 ovarian cancer primary cultures, with a dose-modifying factor ranging from 2.1 to 3.9 for melanomas and from 4.0 to 7.5 for ovarian cancers, respectively. In the remaining cultures, the interaction between fludarabine and cisplatin was additive. The alkaline filter elution analysis performed on primary cultures showed that the synergistic interaction between the two drugs was paralleled by an increase in the extent and persistence of the cisplatin-induced DNA interstrand crosslinks. Our results indicate that fludarabine can enhance cisplatin cytotoxic activity in human tumour primary cultures from ovarian cancer and malignant melanoma. Such an effect may be partially due to an interference by fludarabine on cisplatin-induced DNA adduct metabolism and repair.",
keywords = "Cisplatin, Cytotoxicity, Dna repair, Fludarabine, Malanoma, Ovarian cancer",
author = "N. Zaffaroni and L. Orlandi and D. Gornati and {De Marco}, C. and M. Vaglini and R. Silvestrini",
year = "1996",
language = "English",
volume = "32",
pages = "1758--1765",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "10",

}

TY - JOUR

T1 - Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines

AU - Zaffaroni, N.

AU - Orlandi, L.

AU - Gornati, D.

AU - De Marco, C.

AU - Vaglini, M.

AU - Silvestrini, R.

PY - 1996

Y1 - 1996

N2 - The potential of the purine analogue fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine-5 monophosphate) as a modulator of cisplatin cytotoxicity was investigated in four established cell lines and 20 primary cultures of human melanoma and ovarian cancer. Tumour cells were exposed to fludarabine and cisplatin, alone or in combination, for 4 h. Fludarabine did not affect the growth of ovarian cancer cell lines, whereas it induced a marked and dose-dependent inhibition of proliferation in melanoma cell lines. In primary cultures of both histotypes, the purine analogue did not induce appreciable antiproliferative effects. Combined cisplatin-fludarabine treatment caused additive effects in all established cell lines. Conversely, a synergistic effect of the combination was seen in 5 of 10 melanoma and 4 of 10 ovarian cancer primary cultures, with a dose-modifying factor ranging from 2.1 to 3.9 for melanomas and from 4.0 to 7.5 for ovarian cancers, respectively. In the remaining cultures, the interaction between fludarabine and cisplatin was additive. The alkaline filter elution analysis performed on primary cultures showed that the synergistic interaction between the two drugs was paralleled by an increase in the extent and persistence of the cisplatin-induced DNA interstrand crosslinks. Our results indicate that fludarabine can enhance cisplatin cytotoxic activity in human tumour primary cultures from ovarian cancer and malignant melanoma. Such an effect may be partially due to an interference by fludarabine on cisplatin-induced DNA adduct metabolism and repair.

AB - The potential of the purine analogue fludarabine (9-β-D-arabinofuranosyl-2-fluoroadenine-5 monophosphate) as a modulator of cisplatin cytotoxicity was investigated in four established cell lines and 20 primary cultures of human melanoma and ovarian cancer. Tumour cells were exposed to fludarabine and cisplatin, alone or in combination, for 4 h. Fludarabine did not affect the growth of ovarian cancer cell lines, whereas it induced a marked and dose-dependent inhibition of proliferation in melanoma cell lines. In primary cultures of both histotypes, the purine analogue did not induce appreciable antiproliferative effects. Combined cisplatin-fludarabine treatment caused additive effects in all established cell lines. Conversely, a synergistic effect of the combination was seen in 5 of 10 melanoma and 4 of 10 ovarian cancer primary cultures, with a dose-modifying factor ranging from 2.1 to 3.9 for melanomas and from 4.0 to 7.5 for ovarian cancers, respectively. In the remaining cultures, the interaction between fludarabine and cisplatin was additive. The alkaline filter elution analysis performed on primary cultures showed that the synergistic interaction between the two drugs was paralleled by an increase in the extent and persistence of the cisplatin-induced DNA interstrand crosslinks. Our results indicate that fludarabine can enhance cisplatin cytotoxic activity in human tumour primary cultures from ovarian cancer and malignant melanoma. Such an effect may be partially due to an interference by fludarabine on cisplatin-induced DNA adduct metabolism and repair.

KW - Cisplatin

KW - Cytotoxicity

KW - Dna repair

KW - Fludarabine

KW - Malanoma

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=0009355277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0009355277&partnerID=8YFLogxK

M3 - Article

VL - 32

SP - 1758

EP - 1765

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 10

ER -